New hope for aggressive lung cancer: drug combo trial launches

NCT ID NCT07245446

First seen Jan 05, 2026 · Last updated May 16, 2026 · Updated 19 times

Summary

This study tests whether adding extra drugs to a standard chemotherapy plus ivonescimab regimen can better shrink tumors in people with extensive-stage small cell lung cancer. About 180 adults who have not had prior treatment will be randomly assigned to one of three groups. The goal is to find the safest and most effective combination to control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cancer Hospital Chinese Academy of Medical Sciences

    NOT_YET_RECRUITING

    Beijing, Beijing Municipality, 100020, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Shanghai Pulmonary Hospital Affiliated to Tongji University

    RECRUITING

    Shanghai, Shanghai Municipality, 200433, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • The First Affiliated Hospital of Xi'an Jiaotong University

    RECRUITING

    Xi'an, Shaanxi, 710000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.